Hikma Pharmaceuticals is a multinational pharmaceutical company that develops, manufactures, and markets a broad range of generic, branded, and injectable pharmaceutical products. It is a leading supplier of sterile injectable medicines in the U.S. and operates one of the largest generics businesses in the MENA region.
Company Info
Upcoming Milestones & Key Dates
Q1 2026 Earnings — Injectables franchise and Ohio expansion update
First production from expanded Ohio facilities
Clinical Development Pipeline
Recent News
Hikma announces a $267M investment in Ohio manufacturing, while Cingulate receives a Complete Response Letter from the FDA for its ADHD drug, a separate but related funding story in the same newsletter.
Hikma Pharmaceuticals announced a $267 million investment across its Ohio manufacturing facilities, expected to create 350 new jobs and expand sterile injectable and generic drug production capacity in the U.S. market.
Hikma will funnel $267M to its Ohio operations; Cingulate received a CRL for its ADHD drug.
Leadership Team
Careers & Job Openings